what country is retatrutide available UK Guide: Key Facts on the New Weight-Loss Drug Vial of unapproved peptide retatrutide

What everyone needs to hear: Week 7 is temporary

Some women experience telogen effluvium, a diffuse shedding of hair triggered by metabolic stress during rapid weight loss

Gastrointestinal symptoms that some patients experience while on GLP-1 therapysuch as nausea, reduced appetite, or altered bowel habitsgenerally resolve as the medication clears from the system, typically within 1-2 weeks for short-acting formulations and within 4-8 weeks for long-acting preparations, corresponding to their elimination timelines

Most patients begin to see resultssuch as improved energy, reduced appetite, and weight losswithin a few weeks

Important risk: Diabetic ketoacidosis (DKA) at lower-than-usual blood glucose levels (so-called euglycaemic DKA)

Member States should consider, jointly with marketing authorisation holders, measures to control and optimise the distribution of these medicines